Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Fineline Cube Jul 23, 2026
Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Fineline Cube Jul 23, 2026
Company Drug

Sun-Novo’s STC007 Gains NMPA Approval for Postoperative Pain Study

Fineline Cube Sep 20, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd has announced that it has received approval from...

Company Deals

WuXi Biologics Partners with Elpiscience for Macromolecule Development

Fineline Cube Sep 20, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple...

Company Drug

Tasly Pharmaceuticals Gains NMPA Approval for B1344 Diabetes Study

Fineline Cube Sep 20, 2022

China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National...

Company Drug

Clover Biopharmaceuticals Reports Positive Phase III Data for COVID-19 Vaccine SCB-2019

Fineline Cube Sep 20, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced additional positive Phase III clinical trial data...

Company Drug

RemeGen Announces Positive Phase III Results for Telitacicept in SLE

Fineline Cube Sep 20, 2022

China-based pharma firm RemeGen (HKG: 9995) has announced the conclusion of a Phase III confirmatory...

Company Drug

BeiGene’s Brukinsa Receives New EU and UK Indications for BTK Inhibitor

Fineline Cube Sep 20, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has received two new indication...

Company Drug

Alphamab Oncology Doses First Patient in Phase I Study for JSKN003 in Australia

Fineline Cube Sep 20, 2022

Alphamab Oncology (HKG: 9966) has announced that the first patient has been dosed in a...

Company Deals Hospital

Beijing Launches HIV Precision Medicine Standardization Project

Fineline Cube Sep 20, 2022

On September 17, an HIV precision medicine standardization project was initiated in Beijing. The project,...

Company Deals

Fosun Pharma Signs Exclusive Licensing Deal for H008 with Carephar

Fineline Cube Sep 20, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has signed an exclusive...

Company Deals

Suzhou Weiyou Gene Bio Raises Pre-Series A Funding for Gene Therapy Pipeline

Fineline Cube Sep 20, 2022

China-based Suzhou View Gene Biotechnology Co., Ltd has reportedly raised “tens of millions” of renminbi...

Company Medical Device

Lepu Medtech Receives Approval for Innovative Peripheral Cutting Balloon

Fineline Cube Sep 19, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Deals

Lepu Medtech Prices GDR Offering for International Expansion

Fineline Cube Sep 19, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has priced...

Company Deals

Zhong’ao Biopharmaceutical Secures Series A Funding for Cancer and HPV-Related Disease R&D

Fineline Cube Sep 19, 2022

China-based Zhong’ao Biopharmaceutical Technology (Guangdong) Co., Ltd. has reportedly raised an undisclosed amount of money...

Policy / Regulatory

NHSA Launches Expert Review for 2025 NRDL Update in China

Fineline Cube Sep 19, 2022

The National Healthcare Security Administration (NHSA) announced on September 16 the commencement of the expert...

Company Drug

Daehwa Pharmaceutical Files NDA for Liporaxel in China for Gastric Cancer Treatment

Fineline Cube Sep 19, 2022

South Korea’s Daehwa Pharmaceutical (KOSDAQ: 067080) has announced the filing of a New Drug Application...

Company Drug

Antengene’s ATG-101 Receives Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Sep 19, 2022

China-based biotech Antengene Corp., Ltd (HKG: 6996) has announced that its pipeline candidate ATG-101, a...

Company Deals

Ascletis Pharma and Roche Terminate Promotion Agreement for Pegasys

Fineline Cube Sep 19, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced a supplementary agreement with Swiss pharmaceutical giant...

Company Deals

Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing

Fineline Cube Sep 19, 2022

Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company...

Company

Everest Medicines Appoints Rogers Yongqing Luo as New CEO

Fineline Cube Sep 19, 2022

China-based biotech Everest Medicines (HKG: 1952) has announced the appointment of a new CEO, Rogers...

Drug Policy / Regulatory

Hainan’s Lecheng Zone Updates Special Drug Insurance List with Expanded Coverage

Fineline Cube Sep 16, 2022

Hainan Boao Lecheng International Medical Tourism Pilot Zone has released an updated special drug insurance...

Posts pagination

1 … 656 657 658 … 699

Recent updates

  • MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge
  • CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer
  • PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments
  • Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B
  • OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge

Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Company Drug

Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.